Location History:
- Alberta, CA (2000 - 2014)
- Edmonton, CA (1990 - 2015)
Company Filing History:
Years Active: 1990-2015
Title: B Michael Longenecker: Innovator in Cancer Treatment
Introduction
B Michael Longenecker is a prominent inventor based in Edmonton, Canada. He has made significant contributions to the field of cancer treatment, holding a total of 14 patents. His innovative work focuses on developing vaccines that target specific cancer types, showcasing his dedication to improving patient outcomes.
Latest Patents
Among his latest patents is the Mucinous glycoprotein (MUC-1) vaccine. This invention provides a method for treating individuals afflicted with cancers such as non-small cell lung cancer or prostate cancer. The formulation may be a MUC-1 based liposomal vaccine formulation, which represents a novel approach to cancer therapy. Another notable patent is the method of treating patients with a mucinous glycoprotein (MUC-1) vaccine, which also emphasizes the use of a MUC-1 based formulation for effective treatment.
Career Highlights
Throughout his career, B Michael Longenecker has worked with several notable companies, including Biomira, Inc. and Oncothyreon Inc. His experience in these organizations has allowed him to collaborate with other experts in the field and further his research in cancer treatment.
Collaborations
Some of his coworkers include Carina Henningsson and Babita Agrawal. Their collaboration has contributed to the advancement of innovative solutions in the medical field.
Conclusion
B Michael Longenecker's work in developing cancer vaccines highlights his commitment to innovation and improving healthcare. His contributions continue to pave the way for new treatment options for patients battling cancer.